AstraZeneca’s first foray with PD-L1 inhibitor Imfinzi as a treatment for bladder cancer was a flop. | Following an FDA ...

Regeneron (REGN) stock is in focus as the firm fails in a late-stage trial testing a combination therapy involving its ...

While the fianlimab arm showed a numerical improvement in progression-free survival, the difference was not statistically ...

Merck’s MRK strong oncology sales growth is largely driven by its biggest revenue driver, Keytruda. The blockbuster PD-L1 ...

As breakthrough drugs offer critical hope to patients, lawmakers should focus on shoring up the social safety net ...

Mounjaro surpasses Keytruda top sales with $8.7B in Q1 2025, marking a 125% increase for Eli Lilly over Merck's cancer drug.

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

Merck (NYSE:MRK) is expanding clinical work around KEYTRUDA through a new collaboration with Erasca on ERAS-0015 in ...

Adding Inhibrx Biosciences’ OX40 agonist to Keytruda doubled the response rate in a midphase clinical trial, encouraging the ...

(Reuters) -Merck & Co posted higher third-quarter revenue on Thursday, as growth from its blockbuster cancer drug Keytruda offset falling sales from human papillomavirus vaccine Gardasil in China.

Key growth factors for KEYTRUDA include its unparalleled commercial scale, broad approval across multiple tumor types, strong uptake in early-stage therapies, and a robust clinical trial program.

On the second night of the largest annual European cancer conference, some 100 Merck scientists packed into Champeaux, a classic French restaurant, to break bread and share clinical wisdom. It was ...